Armata Pharmaceuticals (ARMP) Net Income towards Common Stockholders (2016 - 2018)
Historic Net Income towards Common Stockholders for Armata Pharmaceuticals (ARMP) over the last 6 years, with Q4 2018 value amounting to -$8.9 million.
- Armata Pharmaceuticals' Net Income towards Common Stockholders fell 28248.93% to -$8.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$13.6 million, marking a year-over-year increase of 560.57%. This contributed to the annual value of -$53.2 million for FY2024, which is 2270.81% down from last year.
- As of Q4 2018, Armata Pharmaceuticals' Net Income towards Common Stockholders stood at -$8.9 million, which was down 28248.93% from -$1.6 million recorded in Q3 2018.
- Armata Pharmaceuticals' Net Income towards Common Stockholders' 5-year high stood at $14.5 million during Q3 2014, with a 5-year trough of -$14.8 million in Q1 2015.
- Moreover, its 5-year median value for Net Income towards Common Stockholders was -$3.2 million (2015), whereas its average is -$2.7 million.
- Within the past 5 years, the most significant YoY rise in Armata Pharmaceuticals' Net Income towards Common Stockholders was 16367.15% (2014), while the steepest drop was 60644.38% (2014).
- Quarter analysis of 5 years shows Armata Pharmaceuticals' Net Income towards Common Stockholders stood at -$994000.0 in 2014, then crashed by 219.92% to -$3.2 million in 2015, then tumbled by 198.74% to -$9.5 million in 2016, then surged by 75.47% to -$2.3 million in 2017, then tumbled by 282.49% to -$8.9 million in 2018.
- Its Net Income towards Common Stockholders was -$8.9 million in Q4 2018, compared to -$1.6 million in Q3 2018 and -$3.0 million in Q2 2018.